Angelman Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Loss of Drosophila
Geier Benjamin et al. — Fly (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41545316/
- 2.
A de novo genome assembly of an Angelman syndrome pig (Sus scrofa domesticus) model to resolve SNHG14.
Taylor Alasdair J et al. — The Journal of heredity (2 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41795949/
- 3.
Bumetanide as a potential treatment for neurodegenerative and neurodevelopmental disorders: A systematic review.
McNamara Oran et al. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42161225/
- 4.
Nonpharmacological Sleep Interventions for Children With Angelman Syndrome: A Scoping Review.
Barrett Joseph et al. — The American journal of occupational therapy : official publication of the American Occupational Therapy Association (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42102304/
- 5.
Periodic and aperiodic contributions to EEG delta power are translatable and complementary Angelman syndrome biomarkers.
Montgomery Daniel P et al. — Communications medicine (20 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42321460/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
Recruiting — Phase 3 — Ionis Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT06914609
- 2.
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
Recruiting — Phase 1 — Ionis Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT05127226
- 3.
The Global Angelman Syndrome Registry
Recruiting — Foundation for Angelman Syndrome Therapeutics, Australia
https://clinicaltrials.gov/study/NCT05293184
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Angelman Syndrome
Angelman syndrome is a genetic condition affecting the nervous system that causes severe intellectual disability, speech difficulties, seizures, and a characteristically happy, excitable personality. It is caused by a missing or non-working UBE3A gene. Research into gene therapy and UBE3A-targeted treatments is progressing rapidly.
Most Recent Research
Angelman syndrome (AS) is a rare neurogenetic disorder characterized by developmental delay, speech impairment, ataxia, epilepsy, and in some cases hyperphagic feeding behavior. AS is caused by loss of function mutations, loss of expression, or maternal allele deletion of the E3 ubiquitin ligase UBE3A. Recent work has identified a connection between UBE3A and the mechanosensitive ion channel PIEZO2, raising the possibility that UBE3A may regulate PIEZO-dependent satiety signaling. In this study, we investigated the role of the Drosophila UBE3A ortholog, Dube3a, in Piezo-associated feeding behaviors. Single-cell RNA-sequencing data revealed overlapping expression of Dube3a and Piezo within crop and enterocyte populations of the gut, identifying a relevant cellular context for this pathway to occur. We developed a novel feeding assay using GFP-expressing yeast to quantify food intake and gut distention in vivo. Dube3a loss-of-function (Dube3a15b) flies exhibited hyperphagia and gut distention nearly identical to Piezo knockout flies. Analysis of chromosomal deficiency lines spanning the Dube3a locus further supported a requirement for Dube3a in normal satiety signaling. Finally, biochemical analyses demonstrated that Dube3a knockdown results in decreased Piezo protein levels, consistent with an indirect regulatory relationship. Together, these findings identify Dube3a as a critical regulator of Piezo-dependent satiety pathways and suggest that dysregulation of mechanosensory signaling may contribute to hyperphagia observed in AS. Further work is needed to define the intermediate factors linking UBE3A activity to Piezo stability and function.
Common Questions
What is Angelman Syndrome?
Angelman syndrome is a genetic condition affecting the nervous system that causes severe intellectual disability, speech difficulties, seizures, and a characteristically happy, excitable personality. It is caused by a missing or non-working UBE3A gene. Research into gene therapy and UBE3A-targeted treatments is progressing rapidly.
How many clinical trials are available for Angelman Syndrome?
RareWays currently indexes 49 clinical trials for Angelman Syndrome, of which 13 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Angelman Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Angelman Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.